A Phase I Clinical Study of IX001 TCR-T Injection in the Treatment of Advanced Pancreatic Cancer Patients With KRAS G12V Mutation

NCT06898385 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Cancer

Interventions

BIOLOGICAL: IX001 TCR-T injection
DRUG: Fludarabine
DRUG: Cyclophosphamide

Sponsor

Sun Yat-sen University

Collaborators

[object Object]